# US 2010/0168157 A1 · Preventive and therapeutic medicament for gastroesophageal reflux disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168157 A1
- Document ID: US20100168157A1
- Status: Published application
- Kind: A1
- Application number: 12/564,650
- Filed: 2009-09-22
- Published: 2010-07-01
- Earliest claimed: 2000-02-09
- Inventors: Satoshi Yamazaki
- Web page: https://patentgrep.com/patent/US20100168157A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/4743: condensed with ring systems having sulfur as a ring hetero atom
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The compound of the following formula: wherein R1 and R2 independently represent a hydrogen atom or a lower alkyl group; A represents a group selected from the group consisting of 1-azabicyclo[3.2.2]nonyl group, 1-azabicyclo[2.2.2]octyl group, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof or a hydrate thereof has both improving effect on enterokinetic functions and suppressing effect on acid secretion, and also is highly safe. Accordingly, the substance is useful as preventive or therapeutic medicament for a gastroesophageal reflux disease.

## Claims

### Claim at position 1

1-5. (canceled)

### Claim 6

A method for the treatment of gastroesophageal reflux disease comprising administering to a patient in need thereof a therapeutically effective amount of (R)—N-(1-azabicyclo[2.2.2]oct-3-yl)-4,7-dihydro-7-oxo-thieno[3,2-b]pyrid-ine-6-carboxamide or the tautomer thereof or a pharmaceutically acceptable salt, solvate or hydrate thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein the administration is oral.

### Claim 8 (depends on 7)

The method of claim 7, wherein from about 0.001 mg to about 10 mg per day is administered.

### Claim 9 (depends on 7)

The method of claim 7, wherein a tablet or capsule is administered.

### Claim 10 (depends on 6)

The method of claim 6, wherein the (R)—N-(1-azabicyclo[2.2.2]oct-3-yl)-4,7-dihydro-7-oxo-thieno[3,2-b]pyrid-ine-6-carboxamide or the tautomer thereof is in the form of a hydrochloride salt.